Početna › Skleroderma › Kalifornija
Kliničke studije za Skleroderma u državi Kalifornija
13 studija za Skleroderma traži sudionike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Službeni tekst studije (engleski)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- i još 1
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- i još 1
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
U tijeku regrutacijaFaza 1/2
Od 18 do 70 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
U tijeku regrutacijaFaza 1
Od 18 do 70 godina · Oba spola · Ažurirano 28. kol 2026. · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- i još 3
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- i još 2
U tijeku regrutacijaFaza 1
Od 12 do 70 godina · Oba spola · Ažurirano 22. svi 2026. · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. svi 2025. · NCT05892614Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.